Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.68 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266423 | 1.00 | KDM1A (0.68) | KDM1AMAOBMAOARAB9ACA12 | |
| SCHEMBL15099843 | 1.00 | KDM1A (0.68) | KDM1AMAOBMAOARAB9ACA12 | |
| SCHEMBL12971952 | 0.90 | KDM1A (0.71) | KDM1AMAOBMAOARAB9ANPC1 | |
| SCHEMBL15091510 | 0.90 | KDM1A (0.71) | KDM1AMAOBMAOARAB9ANPC1 | |
| SCHEMBL16273398 | 0.88 | KDM1A (0.75) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15091684 | 0.85 | KDM1A (0.68) | KDM1AMAOBMAOACA12CA1 | |
| SCHEMBL28932473 | 0.84 | KDM1A (0.63) | KDM1AMAOBMAOACA12CA1 | |
| SCHEMBL28932474 | 0.84 | KDM1A (0.63) | KDM1AMAOBMAOACA12CA1 | |
| SCHEMBL16273296 | 0.84 | KDM1A (0.77) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15091853 | 0.83 | KDM1A (0.65) | KDM1AMAOBMAOACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708309-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2017-07-18 | — | — | US | disclosed |
| US-9670136-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2017-06-06 | — | — | US | disclosed |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2017-01-12 | — | — | US | disclosed |
| US-20160368857-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2016-12-22 | — | — | US | disclosed |
| US-9487512-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2016-11-08 | — | — | US | disclosed |
| US-9469597-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2016-10-18 | — | — | US | disclosed |
| US-20150376177-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2015-12-31 | — | — | US | disclosed |
| US-9181198-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS S.A. (ES) | 2015-11-10 | — | — | US | disclosed |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2015-01-22 | — | — | US | disclosed |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2014-09-11 | — | — | US | disclosed |
| US-20130231342-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | Oryzon Fenomics S.A. (ES) | 2013-09-05 | — | — | US | disclosed |
| WO-2012013728-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368857-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 147/4885MAOA 135/4885 |
| US-20150119396-A9 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM3B | KDM1A 1/4885MAOB 186/4885MAOA 175/4885 |
| US-20130231342-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | KDM6A, KDM1B, KDM1A | KDM1A 3/4885MAOB 66/4885MAOA 52/4885 |
| US-20170008844-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 165/4885MAOA 143/4885 |
| US-20150376177-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | KDM6A, KDM1B, KDM1A | KDM1A 3/4885MAOB 66/4885MAOA 52/4885 |
| US-20140256729-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM3B | KDM1A 1/4885MAOB 186/4885MAOA 175/4885 |
| US-20150025054-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAOB 165/4885MAOA 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.